Actively Recruiting
Phase 1 Open-Label Study Evaluating Safety and Effects of BL-M14D1 in Adults with Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Led by SystImmune Inc. · Updated on 2026-10-30
120
Participants Needed
31
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and effectiveness of a drug called BL-M14D1 in adults with locally advanced or metastatic small cell lung cancer and other neuroendocrine tumors. This Phase 1 open-label study aims to understand how this drug behaves in the body and its potential impact on these serious cancers, especially in patients who have already tried standard treatments or cannot receive them. Participants will receive BL-M14D1 through an intravenous infusion on the first day of each 3-week cycle. The study includes multiple groups, including a dose expansion cohort for patients with tumors expressing a specific marker called DLL3. Treatment continues in cycles, and participants are monitored closely for responses and side effects. During the study, participants will undergo regular safety and health assessments, including evaluations of organ function, heart performance, and tumor size using standard criteria. Researchers will track how the drug is processed in the body and its antitumor activity over approximately 18 months. This monitoring helps assess safety, effectiveness, and how well the treatment is tolerated.
CONDITIONS
Brief Title
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Research Team
L
Lien Huzzy
W
Whitney Eakins
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here